| T35333 |
ARRY-382
|
1313407-95-2
|
98%
|
|
|
ARRY-382 is a highly selective oral inhibitor of CSF-1R with an IC50 of 9 nM.
|
| T77125 |
Otilimab
|
1638332-55-4
|
98%
|
Otilimab
|
|
Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF). Otilimab has anti-inflammatory activi...
|
| T76690 |
Mavrilimumab
|
1085337-57-0
|
98%
|
Mavrilimumab
|
|
Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that has an affinity for the α subunit of the granulocytic-macrophage colony-stimulating...
|
| T4315 |
Ki20227
|
623142-96-1
|
|
|
|
Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451...
|
| T1667 |
Tandutinib
|
387867-13-2
|
|
|
|
Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus...
|
| T64066 |
CSF1R-IN-3
|
2760584-90-3
|
97.31%
|
|
|
CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM. CSF1R-IN-3 has anti-proliferative activity against colorectal cancer cells. CSF1...
|
| T6119 |
Sotuletinib
|
953769-46-5
|
97.43%
|
|
|
Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase...
|
| T2514 |
Linifanib
|
796967-16-3
|
98%
|
|
|
Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDG...
|
| T14380 |
AZD7507
|
1041852-85-0
|
98.01%
|
|
|
AZD7507 is a CSF-1R inhibitor with an IC50 of 32 nM. AZD7507 has antitumor activity.
|
| T15199 |
Edicotinib
|
1142363-52-7
|
98.58%
|
|
|
Edicotinib (JNJ-527) is a brain penetrant and orally active inhibitor of the colony-stimulating factor-1 receptor (IC50: 3.2 nM). It shows less inhibitory effect...
|
| T10652 |
Vimseltinib
|
1628606-05-2
|
98.98%
|
|
|
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM).
|
| T4376 |
Nampt-IN-1
|
1698878-14-6
|
99.4%
|
|
|
Nampt-IN-1 (LSN3154567) (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.
|
| T2115 |
Pexidartinib
|
1029044-16-3
|
99.66%
|
|
|
Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antin...
|
| TQ0015 |
PRN1371
|
1802929-43-6
|
99.72%
|
|
|
PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).
|
| T2624 |
OSI-930
|
728033-96-3
|
99.76%
|
|
|
OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
|
| T7100 |
PLX5622
|
1303420-67-8
|
99.89%
|
|
|
PLX5622 is a highly selective brain penetrant and oral active CSF1R inhibitor.
|
| T10647 |
C-Fms-IN-8
|
1255303-58-2
|
98%
|
|
|
c-Fms-IN-8 is a colony-stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor (IC50: 9.1 nM). It is compound 4a in the reference.
|
| T11390 |
GENZ-882706
|
2070864-35-4
|
98%
|
|
|
GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.
|
